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Objectives: The objectives were 1) to elicit relative preferences for attributes of antiretroviral 
therapies (ART) in people living with HIV (PLWH) and 2) to explore satisfaction and adherence 
with current ART.
Patients and methods: We conducted a multicenter cross-sectional study, consecutively 
enrolling PLWH receiving an ART. The quantitative part estimated the strength of preference 
for different attributes using an online discrete choice experiment (DCE). DCE data were ana-
lyzed using a mixed logit regression model. Qualitative data were collected through individual 
interviews. A preliminary coding framework was developed which was then further refined and 
applied during thematic analysis of factors influencing satisfaction and adherence.
Results: A total of 101 PLWH took part in the quantitative part and 31 in the qualitative 
part. Over 90% had an undetectable viral load. Quantitative data revealed a strong preference 
for a treatment with limited drug–drug interactions, diarrhea and long-term health problems 
(P0.0001), and that did not need to be taken on an empty stomach (P0.0001). Patients also 
preferred to avoid problems associated with treatment failure (P0.0001) or one that left them 
with a higher viral load after the first weeks of treatment (P0.044). Differences in CD4 cell 
count, and pills that must be taken with food were not significant drivers of treatment choice. 
The strength of these attributes was reflected in the qualitative data, highlighting the importance 
patients place on treatment efficacy, and also suggesting that some of these attributes may impact 
adherence. Many factors influencing adherence and satisfaction with treatment were identified, 
including pill size, worry about sexual transmission and impact on social life.
Conclusion: Most of the attributes included in this survey were important to participants when 
choosing an ART, in particular those related to quality of life, and these should be taken into 
account in order to optimize adherence and satisfaction.
Keywords: antiretroviral therapy, adherence, HIV infection, preference elicitation, satisfac-
tion, ARV treatments
Introduction
The treatment of human immunodeficiency virus (HIV) infection using current 
antiretroviral drugs (ARVs) is more effective, better tolerated and simpler to admin-
ister than regimens used in the past.1 This therapeutic advance has contributed to a 
dramatic reduction in HIV-associated morbidity and mortality in people living with 
HIV (PLWH), and has changed HIV into a chronic, manageable disease.1
There are now only small efficacy differences between available treatments. As a 
result, the choice of treatment is based mainly on the side-effect profile of the ARV, 
drug interactions, resistance barriers, the pharmaceutical form and patient preference. 
The current approach to the treatment of HIV now allows the patient an increasingly 
important role in the choice of treatment, with the aim of ensuring maximum adherence.2 
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To ensure optimum efficacy at the beginning of treatment, 
95%–100% adherence is necessary, but despite this, various 
studies show that adherence remains inadequate.3–6
The majority of existing studies to understand patient 
preferences for HIV treatment have focused on factors 
affecting treatment adherence, because patient satisfaction 
with HIV care and treatment can have a direct impact on 
adherence.7 Factors related to adherence can be broadly 
divided into three groups, namely treatment-related factors 
(usually attributes of the medication), social factors (relating 
to patient characteristics or environment) and disease char-
acteristics (eg, CD4 cell count).7 A number of studies have 
explored adherence factors linked to treatment.8–10 In particu-
lar a European study identified five treatment attributes influ-
encing patient adherence, namely administration frequency, 
daily pill burden, number of pills per dose, side effects and 
effectiveness.11 Side effects and effectiveness were found 
to be most important to PLWH across all five countries.11 
A recent systematic literature review found that patients who 
experienced asthenia, confusion, taste disturbances or nausea 
were less likely to adhere to treatment compared to those who 
did not experience any side effects.12 Perceived effectiveness 
is another important factor in patient satisfaction and adher-
ence to medication.13 In addition, frequency of treatment 
administration is also a key predictor of patient adherence.14 
Patient preference and adherence are improved with simple 
dosing regimens, particularly once-daily dosing; crucially 
this factor can often determine the difference between suc-
cess and failure of an ARV regimen.15–18
Other studies have shown that factors related to patient char-
acteristics and social support also play a role in patient adherence 
to HIV medication.7,19–22 The characteristics of HIV infection, 
the emotional impact of HIV, the quality of the patient/doctor 
relationship and the patient’s knowledge about the treatment can 
also influence their satisfaction and adherence.23–28
Although many studies have focused on one or more of 
these treatment factors, only one study was identified which 
compared the relative importance of these different factors 
or the relationships between them at the time we started our 
study. This US preference study asked 35 PLWH to make 
trade-offs between various treatment attributes including 
treatment efficacy, resistance, side effects and convenience. 
The risk of developing resistance, regimen convenience 
and the risk of sleep disturbance had the greatest impact on 
patient treatment preferences. Other side effects most likely 
to influence patient satisfaction included cholesterol eleva-
tion, nausea and diarrhea.29
Given the multiplicity of factors influencing adherence 
to and satisfaction with ARV treatment, it is becoming more 
widely acknowledged that treatment must be individually tai-
lored, with the choice of treatment and follow up taking into 
account those factors considered most important by patients. 
Better understanding of these mechanisms would enable 
better matching of treatments to patient expectations. With 
the development of new ARV therapies, it is also important 
to determine whether there remain unmet needs in the care 
and treatment of PLWH.
The objective of this study was to elicit patient prefer-
ences regarding the principal characteristics of ARV thera-
pies and to explore satisfaction of PLWH in France with their 
current ARV therapies. The study was composed of two parts, 
a quantitative study to estimate the relative strength of prefer-
ence for different attributes associated with ARV therapies, 
and a qualitative study designed to assess factors influencing 
patient satisfaction. In addition, it was anticipated that the 
qualitative part of the study would aid interpretation of the 
quantitative part, and provide more detailed understanding 
of the drivers of patient preferences for treatment.
Patients and methods
This multicenter, cross-sectional, observational epidemiolog-
ical study was one of five parallel, identical studies conducted 
in five European countries (France, Italy, Spain, Germany 
and the UK). The French study was conducted between 
April and July 2014 in five hospitals and was overseen by 
an independent scientific committee with representatives of 
health care professionals and patient organization. The study 
was approved by the Nord-Ouest III Ethics Committee, the 
French Consultative Committee on Data Processing for 
Healthcare Research and the French National Data Process-
ing and Freedoms Commission.
Patients
The eligibility criteria were identical for both parts of the 
study. To be included, patients had to be at least 18 years old, 
to be a current resident in France, to be taking ARV therapy 
and to have appropriate verbal and written language skills in 
French. Patients taking part in a clinical trial, acutely unwell 
or suffering from cognitive impairment that, in the opinion of 
the investigator, would interfere with the study requirements 
were excluded in the study.
Patients were selected consecutively from clinic lists by 
the investigators at each center. They could participate in one 
or both studies but there was no obligation to participate in 
both. The following sociodemographic characteristics were 
considered during patient recruitment: gender, mode of trans-
mission, country of transmission, type of ARV treatment, 
duration of ARV regimen, hepatitis B and C coinfection 
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status. This recruitment methodology aimed to achieve an 
epidemiologically representative sample of PLWH. Eligible 
patients interested in participating completed a written 
informed consent form with the physician.
4XDQWLWDWLYHVWXG\
Patient preferences for attributes (characteristics) of ARV 
treatment were evaluated using discrete choice experiment 
(DCE) methodology.30–32 A DCE survey is designed to under-
stand the strength of patient preference for different treatment 
characteristics. This method consists of presenting patients 
with different therapies presented pairwise and patients have 
to choose one or other of the treatment options.
&RQVWUXFWLRQRIWKH'&(
The treatment attributes for this study were defined on the 
basis of a literature review and the opinion of the European 
advisory board (including a French expert, PLWH and 
health care professionals). The levels of these attributes 
were identified through existing clinical information, input 
from clinicians (to determine relevance and thresholds for 
clinical characteristics such as the risk of side effects), and 
input from a DCE design expert (to ensure optimal design of 
the survey during construction). The aim of the attribute and 
level development was to include treatment attributes that are 
clinically specific, relevant and comprehensible to PLWH.
The list of eleven attributes proposed by the advisory 
board underwent a pilot test in one-on-one interviews with five 
PLWH. During these interviews, patients were asked to discuss 
each attribute in detail to determine its relevance to treatment 
satisfaction and provide feedback on the language used in the 
attribute levels. Patients were also asked to rank the attributes in 
terms of importance and to explain their ranking. This exercise 
proved important in both revising the wording of the attributes 
and reducing the final number of attributes from eleven to seven. 
These seven attributes and levels (three levels for each attribute) 
were then included in the DCE survey (Table 1).
The levels of attributes were then combined into choice 
sets. The total number of possibilities is obtained by com-
bining the number of attributes with the number of levels 
determined for each attribute, so for this study 372,187 
scenarios. To minimize the number of possible choice sets 
(to minimize patient burden), also to obtain a maximum 
level of information, an orthogonal array was used to select 
18 scenarios, with an additional repeated choice set to test 
participant comprehension of the task (consistency check). 
The final survey consisted of 19 choice sets, each compris-
ing a choice between two treatments (treatment A versus 
treatment B). The order of choice sets was randomized for 
each patient in order to avoid potential ordering effects 
(Table 2 shows an example choice set). Patients were asked 
to choose which treatment option they would prefer.
6DPSOHVL]HIRUWKH'&(VXUYH\
For DCE studies, conventional calculations of sample size 
are inappropriate and no formal recommendations exist 
Table 1'LVFUHWHFKRLFHH[SHULPHQW²DWWULEXWHVDQGOHYHOV
Attributes Levels
Viral load reduction An undetectable viral load (FRSLHVP/ZLWKLQZHHNVUHPDLQLQJXQGHWHFWDEOHDIWHUPRQWKV
$YLUDOORDGDURXQGFRSLHVP/ZLWKLQZHHNVDQGXQGHWHFWDEOHDIWHUPRQWKV
$YLUDOORDGDURXQGFRSLHVP/ZLWKLQZHHNVDQGXQGHWHFWDEOHDIWHUPRQWKV
&'FHOOFRXQWLQFUHDVH $QLQFUHDVHRI&'100/mmDIWHUPRQWKVRIWUHDWPHQW
$QLQFUHDVHRI&'50/mmDIWHUPRQWKVRIWUHDWPHQW
$QLQFUHDVHRI&'25/mmDIWHUPRQWKVRIWUHDWPHQW
6LGHHIIHFWVGLDUUKHD <RXGRQRWH[SHULHQFHORRVHVWRROVDVDUHVXOWRI\RXUWUHDWPHQW
<RXH[SHULHQFHHSLVRGHVRIORRVHVWRROVSHUGD\DVDUHVXOWRI\RXUWUHDWPHQW
<RXH[SHULHQFHPRUHWKDQHSLVRGHVRIORRVHVWRROVSHUGD\DVDUHVXOWRI\RXUWUHDWPHQW
/RQJWHUPKHDOWKSUREOHPVERQH 
NLGQH\GLVHDVHRUKHDUWGLVHDVH
1RLQFUHDVHGULVNRIGHYHORSLQJIXWXUHKHDOWKSUREOHPV
LQSHRSOHZLOOH[SHULHQFHIXWXUHKHDOWKSUREOHPV
LQSHRSOHZLOOH[SHULHQFHIXWXUHKHDOWKSUREOHPV
Treatment failure $OOWUHDWPHQWRSWLRQVDUHDYDLODEOHWR\RX
6RPHDQWLUHWURYLUDOWUHDWPHQWVDUHRQO\SDUWLDOO\HIIHFWLYH
6RPHDQWLUHWURYLUDOWUHDWPHQWVFDQQRWEHXVHGZKLOHRWKHUVDUHRQO\SDUWLDOO\HIIHFWLYH
Food restrictions 1RVSHFLÀFIRRGUHTXLUHPHQWV
$OOSLOOVPXVWEHWDNHQZLWKIRRG
$OOSLOOVPXVWEHWDNHQRQDQHPSW\VWRPDFK
'UXJ²GUXJLQWHUDFWLRQ No drug interactions occur
<RXFDQWDNHRWKHUPHGLFDWLRQEXW\RXUGRVHRI+,9WUHDWPHQWZLOOEHDGMXVWHGDQGWKLVPD\OHDG
to a greater chance of side effects
<RXFDQQRWWDNHFHUWDLQPHGLFDWLRQV
Abbreviation:+,9KXPDQLPPXQRGHÀFLHQF\YLUXV
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regarding the number of subjects to be included. However, 
Pearmain et al suggested a minimum sample size of 100 
individuals to elicit patient preference.33
$QDO\VLVRIWKH'&(
A descriptive analysis of the demographic data was con-
ducted. Statistical analysis of the data was carried out using 
a mixed logit regression model to evaluate patient prefer-
ence for each treatment attribute. The strength of patient 
preference for each attribute is determined by the odds ratio 
(OR) and its 95% confidence interval (CI), which indicates 
the odds of preferring a level of an attribute compared to a 
reference level of the same attribute (all other things being 
equal). The reference levels chosen for each attribute are 
the “most preferred” levels. The significance of a specific 
attribute level refers to whether it has an association with 
patient preference. Thus, as the adjusted OR moves below 1, 
there is less chance of choosing a treatment with this level, 
compared to the reference level.
4XDOLWDWLYHVWXG\
The qualitative phase of the study involved an in-depth 
semistructured telephone interview of PLWHs. It was con-
ducted in order to help interpretation of the DCE results, in 
addition to exploring other factors that influence satisfaction 
and adherence.
'HYHORSPHQWRIWKHLQWHUYLHZJXLGH
Three distinct groups of factors having a significant influence 
on treatment satisfaction for PLWH were identified through 
a focused literature review (medication-related factors, 
patient-related factors and physician-related factors) and 
were included as questions in the patient interview guide.8,28 
Questions exploring relationships between the different 
factors were also included, as well as how these factors 
influenced satisfaction and adherence to treatment.
The European version of the interview guide was final-
ized after a pilot focus group carried out with five PLWH to 
confirm the acceptability and wording, and then translated 
into French using a full forward-back-translation process.
Participant interviews
Patients were interviewed by an experienced qualitative 
researcher and all interviews were audio-recorded. Patients 
were compensated for the time spent with a 30 gift token.
Based on the previous similar qualitative work, this study 
aimed to recruit a sample size of 30 patients. Final sample 
size was determined using the concept of data saturation: the 
point at which no new information is obtained from additional 
qualitative data.34,35
'DWDDQDO\VLV
A descriptive analysis of the demographic data was carried 
out. The systematic thematic analysis of the transcripts was 
assisted by qualitative analysis software (MAXQDA 10). This 
approach involved two analysts interpreting the transcripts 
for emerging themes and coding them accordingly. All 
themes and associated subthemes that arose from the data 
were recorded in a saturation table.36–38 Recruitment was 
considered complete at the point at which no new information 
was obtained from additional qualitative data.
Results
&KDUDFWHULVWLFVRIWKHVWXG\VDPSOH
The DCE survey was completed by 101 patients (enrolled by 14 
physicians). Most of the patients were male (76%), with a mean 
Table 2'LVFUHWHFKRLFHH[SHULPHQW²H[DPSOHRIDFKRLFHVHW
Choice 12 Treatment A Treatment B
Viral load reduction $YLUDOORDGDURXQGFRSLHVP/ZLWKLQ
ZHHNVDQGXQGHWHFWDEOHDIWHUPRQWKV
An undetectable viral load (FRSLHVP/
ZLWKLQZHHNVUHPDLQLQJXQGHWHFWDEOHDIWHU 
PRQWKV
&'FHOOFRXQWLQFUHDVH $QLQFUHDVHRI&'100/mmDIWHUPRQWKV 
of treatment
$QLQFUHDVHRI&'50/mmDIWHUPRQWKV 
of treatment
'LDUUKHD You experience more than 6 episodes of loose 
VWRROVSHUGD\DVDUHVXOWRI\RXUWUHDWPHQW
You do not experience loose stools as a 
UHVXOWRI\RXUWUHDWPHQW
/RQJWHUPKHDOWKSUREOHPVERQH
NLGQH\GLVHDVHRUKHDUWGLVHDVH
LQSHRSOHZLOOH[SHULHQFHIXWXUHKHDOWK
problems
LQSHRSOHZLOOH[SHULHQFHIXWXUH
health problems
Treatment failure 6RPHDQWLUHWURYLUDOWUHDWPHQWVDUHRQO\SDUWLDOO\
effective
Some antiretroviral treatments cannot be 
XVHGZKLOHRWKHUVDUHRQO\SDUWLDOO\HIIHFWLYH
Food restrictions 1RVSHFLÀFIRRGUHTXLUHPHQWV $OOSLOOVPXVWEHWDNHQZLWKIRRG
'UXJ²GUXJLQWHUDFWLRQ <RXFDQWDNHRWKHUPHGLFDWLRQEXW\RXUGRVHRI
+,9WUHDWPHQWZLOOEHDGMXVWHGDQGWKLVPD\OHDG
to a greater chance of side effects
<RXFDQQRWWDNHFHUWDLQPHGLFDWLRQV
:KLFKWUHDWPHQWGR\RXSUHIHU"  
Abbreviation:+,9KXPDQLPPXQRGHÀFLHQF\YLUXV
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age of 46. Patients had been diagnosed with HIV for a mean of 
12 years, and 96% had an undetectable viral load. The sample 
contained a variety of educational levels, with 8 patients having 
no formal qualification or diploma (8%), 21 patients having 
national vocational qualification level 1, 2 (21%), 21 patients 
having high-school diplomas (21%), 21 patients having short 
higher education (21%) and 18 patients having long higher 
education (18%). Nine patients had another educational level 
(9%) and three patients preferred not to answer (3%).
Thirty-one patients were interviewed for the qualitative 
part (enrolled by ten physicians). No new themes were intro-
duced in the final ten interviews (considered to have reached 
data saturation). This suggests that the sample size is adequate 
and additional interviews would have been unlikely to intro-
duce additional concepts. Most of the patients were male 
(77%), with a mean age of 50. Patients had been diagnosed 
with HIV for a mean of 15 years, and 94% had an undetect-
able viral load. Twenty-one patients participated in both 
studies. Patient characteristics are presented in Table 3.
$QDO\VLVRIWKHTXDQWLWDWLYHVWXG\'&(
Of the 101 patients enrolled, three did not meet the con-
sistency check and were excluded from the DCE analysis. 
Figure 1 presents ORs and their CIs for each of the seven 
attributes. Most of these attributes were significant predictors 
of patient choice. Patients had lower preference for a treat-
ment that resulted in higher viral load of 1,000 copies/mL 
after 4 weeks of treatment compared to 50 copies/mL (OR: 
0.819; CI: 0.674–0.995; P0.044). This is expected, because 
higher viral load implies high disease activity, which is not 
preferred. However, relatively small increases in CD4 count 
of 50/mm3 or 25/mm3 (compared to 100/mm3) was not a 
statistically significant predictor of patient preference.
Patients placed significant value on the avoidance of side 
effects, especially diarrhea. Compared with a treatment that does 
not cause loose stools, patients were 69% less likely to prefer a 
treatment associated with frequent diarrhea (six loose stools a 
day) (OR: 0.309; CI: 0.238–0.402; P0.001) and also strongly 
preferred to avoid treatments with three episodes of loose stools 
per day (OR: 0.685; CI: 0.569–0.824; P0.001). This shows 
the importance given to this adverse effect.
Patients also showed their preference for avoiding some 
of the longer term toxicities, such as cardiovascular disease 
and kidney disease. Compared with a treatment without 
increased risk, patients were 47% less likely to choose a treat-
ment associated with a 10% long-term risk of such problems 
(OR: 0.534; CI: 0.442–0.645; P0.001). Patients were 77% 
less likely to choose a treatment with a 20% long-term risk 
(OR: 0.229; CI: 0.178–0.294; P0.001).
Patients indicated that it was important for them to avoid 
treatment failure which would affect the efficacy of other 
ARVs (OR: 0.659; CI: 0.543–0.800; P0.001). Patients 
strongly preferred avoiding treatment failure if it meant 
Table 3 Patient characteristics
Qualitative  
data, n31a
Quantitative  
data, n101b
Age (years)
0HDQ6'  
Range 2778 2574
Missing data 0 0
Gender
Male/female 24  

7  

77  

24 

Missing data 0 0
Years since diagnosis
0HDQ6'  
Range ² ²
Missing data 1 0
Current viral load
Nondetectable/ 
detectable
29  

2  

97  

4  

Missing data 0 0
Most recent CD4 count (/mm3
200  
200400  
400  
Not sure 0 
Missing data 0 0
Number of years on HIV medication (year)
10  
410  
²  
1  
Missing data 1 0
Number of times switched medication
RUPRUHWLPHV  
Twice  
Once  
Never  
Missing data 1 1
Current ARV therapyc
NNRTI  
Protease inhibitors  
Integrase inhibitors  
CCR5 inhibitors  
Missing data 2 5
Notes: a'DWD FRPSOHWHG E\ WKH LQYHVWLJDWRUV b'DWD FRPSOHWHG E\ WKH SDWLHQWV
c6RPHFRPELQDWLRQVFRQWDLQPRUHWKDQWZRWKLUGDJHQWV
Abbreviations: $59 DQWLUHWURYLUDO GUXJV +,9 KXPDQ LPPXQRGHÀFLHQF\ YLUXV
6'VWDQGDUGGHYLDWLRQ
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that other drugs could not be used at all (OR: 0.556; CI: 
0.455–0.680; P0.001).
Patients were concerned about the potential risk of drug–
drug interactions (DDI), mostly about treatments where a 
potential DDI would lead to a dose adjustment and increased 
risk of side effects (OR: 0.542; CI: 0.449–0.654; P0.001). 
The use of ARVs which precluded the use of other drugs 
because of DDI was also an important concern (OR: 0.603; 
CI: 0.493–0.737; P0.001).
Patients were less concerned about food constraints. 
Treatments with no restrictions around food intake were not 
significantly preferred to those that needed to be taken with 
food. Patients significantly preferred to avoid treatments 
that needed to be taken on an empty stomach (OR: 0.598; 
CI: 0.487–0.733; P0.001).
$QDO\VLVRIWKHTXDOLWDWLYHVWXG\
Treatment attributes
The majority of patients equated an effective treatment with a 
reduction in their viral load and an increase in their CD4 cell 
count. Some also reported that they knew their treatment to be 
effective because they achieved or maintained an undetectable 
viral load.
Patients commonly reported having experienced diarrhea 
as a result of their current medication. For some, this only 
occurred at the beginning of their treatment and had reduced 
or disappeared as they had adjusted to their medication but 
a few patients spoke about an impact on their social life. 
Despite having experienced some sort of side effect either 
from previous or current medication, the majority of patients 
were satisfied with their current treatment in terms of effi-
cacy and convenience and they reported not being worried 
or concerned about these side effects.
Nearly all patients reported that they were aware of the 
potential long-term health problems associated with ARV 
therapies, including risk of cardiovascular disease, osteopo-
rosis, raised cholesterol, liver damage and kidney damage. 
Most patients expressed some level of concern about these 
potential long-term effects and a few reported that they had 
already experienced some of these.
Several patients reported finding the restrictions on when to 
take their medication more inconvenient or difficult to adhere 
to if they were not feeling hungry when they were supposed 
to take it, or if they were away from home in a location where 
other people may see them taking their medication.
Regarding DDI, patients reported feeling that they had 
been well informed about the risks involved with drug 
interactions and had discussed these with their doctor. 
Patients generally felt that they trusted their doctor to pre-
scribe medications that are safe to take in combination, and 
Figure 1 'LVFUHWHFKRLFHH[SHULPHQWUHVXOWV
Abbreviations:$59DQWLUHWURYLUDOGUXJ&,FRQÀGHQFHLQWHUYDOV16QRWVLJQLÀFDQW
??????????????????????????????? ??????????
????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????
???????????????????????????????????????????????????
??????????????????????????????????
?????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????
???????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
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?????????????????????????????????????????????????????????
???????????????????????????????????????
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????????????????????
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????????????????????
????????????????????
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were comfortable discussing these issues with their doctor, 
if necessary.
Concept elicitation
Broader concepts were also covered during the interviews. 
A wide range of themes emerged from the qualitative study 
and were categorized into 16 themes and 112 subthemes. The 
conceptual model demonstrates how these multiple themes 
influence treatment satisfaction and medication adherence.
3DWLHQWVDWLVIDFWLRQZLWK$59WKHUDS\
Satisfaction regarding medication characteristics is described 
through patient quotes in Table 4. Interviewed patients 
were mostly satisfied with the packaging, color, shape 
and size of tablets, as well as their texture, taste and smell 
(quotes a–f).
Most participants reported no impact on body image due 
to ARV therapy. The few participants who reported changes 
spoke of gaining weight and experiencing lipodystrophy. 
Table 44XDOLWDWLYHVWXG\²SDWLHQWTXRWHV
Patient satisfaction with ARV therapy
a ´7KHFRORUVKHOSPHWRWDNHWKHULJKWWDEOHWVµ
´,WJRHVGRZQHDVLO\7KHUHLVQHLWKHUWDVWHQRUWH[WXUHLQIDFW,MXVWVZDOORZLWDQGWKDWLVLWµ
´2WKHUVLQWKHSDVWZHUHQRWVRHDV\,KDGWRJHWVRPHEUHDGDIWHUZDUGVµ
´1RWKH\GRQRWKDYHDQ\WDVWH7KH\DUHHDV\WRVZDOORZµ
b ´<HVIUDQNO\,GRQ·WWKLQNLW·VDJRRGLGHDWRVKRZWKHER[HVRQ79EHFDXVHLILQ\RXUIDPLO\\RXKDYHVRPHRQHZLWKWKHPHGLFDWLRQWKH\
FDQÀQGRXWDQGVXVSHFWDQGWKDW·VQRWJRRG,WFRXOGEHLPSURYHGUHDOO\LQVWHDGRIORRNLQJOLNH¶+,9ER[HV·µ
c ´%XWWKHSUREOHPLVZRUU\DERXWWKHFRORURI$59QDPHZKLFKLVEOXHDQGLI\RXDUHDURXQGLQSXEOLFZLWKSHRSOHZKRDUHWDNLQJSLOOVWKHVH
DUHDOOZKLWHVRWKH\NQRZZKDW\RXDUHWDNLQJµ
d ´6RPHWLPHV,IHHOLWGRHVQRWJRGRZQLWUHPDLQVLQWKHWKURDWµ
´,WERWKHUHGPHDWÀUVW$Q\ZD\WKLVLVWKHWUHDWPHQWWRVXUYLYHZHPXVWPDNHRXUFKRLFHµ
e ´<HVEXWLW·VDOVRWKHVKDSH,WLVELJLIWKH\PDGHWKHPURXQGHUVRWKH\ZHUHHDVLHUWRWDNHµ
f ´:KHQ\RXVHHWKHQXPEHURIWDEOHWVLWZDVEHIRUH,ÀQGLWFXUUHQWWUHDWPHQWJUHDW,WDNHIHZHUWDEOHWVWKDQSHRSOHZKRKDYHGLDEHWHVRU
RWKHUFKURQLFGLVHDVHVµ
´1R,SUHIHUWRWDNHWKHPDOODWRQFH7KDWLVPXFKHDVLHU$QGLWLVJRRGWRWDNHWKHVHLQWKHPRUQLQJEHFDXVH,FDQJRZDQGHULQJDIWHU,WLV
DOZD\VDQQR\LQJLI,KDYHWRWDNHWKHPZLWKPHDOOGD\µ
g 'LGLWPRGLI\\RXUERG\LPDJH"´1R:HOO,WDNHFDUHRIP\VHOIDOLWWOHPRUHµ
h 'LGLWPRGLI\\RXUERG\LPDJH"´,W·VWKHZHDNOLQNUHDOO\+DYLQJJDLQHGNJLVDELWGLIÀFXOWIRUPHLQWHUPVRIVHOIHVWHHP,IHHOOHVV
FRQÀGHQW2IFRXUVHEHDXW\LVVXEMHFWLYHµ
Factors affecting adherence
i ´6KHJLYHVPHWKHLQIRUPDWLRQHYHU\WLPH,VHHKHUDQGWKHODVWWLPH,VDZKHUVKHVKRZHGPHWKHJUDSKRIWKHHYROXWLRQDQGLWZDVUHDOO\
LQWHUHVWLQJEHFDXVHVHHLQJWKHUHVXOWVHDFKWLPHLVJRRGEXWVHHLQJWKHHYROXWLRQLVHYHQPRUHLPSRUWDQWEHFDXVHWKHUHZDVDGHFUHDVHRYHU
WKH\HDUDQGWKHYLUDOORDGGHFUHDVLQJDQGWKHQEHFRPLQJXQGHWHFWDEOHIRUWKHODVW\HDUV,WLVYLVXDODQGSXVKHV\RXWRWDNH\RXU 
WUHDWPHQWFRUUHFWO\µ
´7KHGRFWRUJLYHVPHLQIRUPDWLRQRQP\YLUDOORDG&'HWFDOOWKHWLPH)RUDPRQWK,IRUJRWWRWDNHP\PRUQLQJWDEOHWDQG,ZHQWIURP
XQGHWHFWDEOHYLUDOORDGWRGHWHFWDEOHYLUDOORDG,WLVYHU\TXLFNµ
´,GRQRWZDQWWRPLVVDQ\GRVHDFWXDOO\,WKDVEHFRPHSDUWRIP\KDELWV7KDWZRXOGDIIHFWWKHXQGHWHFWDEOHYLUDOORDGVR,DPEHLQJYHU\
FDUHIXOZLWKWKDWµ
M ´7KHIDFWWKDWWKHPHGLFDWLRQEORFNVWKHLQIHFWLRXVSURFHVV\HVRIFRXUVHLWPDNHV\RXWDNHLWHYHU\GD\5HJXODUO\µ
N 'RZRUULHVDERXWVH[XDOWUDQVPLVVLRQPDNH\RXPRUHHDJHUWRWDNH\RXUPHGLFDWLRQ"
´<HVLWGHÀQLWHO\LQFLWHVPHWRWDNHWKHPµ
l ´,UHDOO\FRPSO\WRDYRLGUHVLVWDQFHNQRZLQJWKDW,ZDVGLDJQRVHGZLWKELOOLRQVRIYLUXVHVLQP\EORRGVWUHDP,ZDVZHHNVIURPGHYHORSLQJWKH
IXOOEORZQGLVHDVH6R,DPYHU\FDUHIXODERXWUHVLVWDQFHµ
´,DPZRUULHGWKDWRQHGD\WKHWUHDWPHQWZLOOVWRSZRUNLQJ7KDW·VZK\,DPYHU\FRPSOLDQWµ
m ´,KDYHKHDUGDERXWWKDW$IWHUDZKLOHZHVKRXOGFKDQJHPHGLFDWLRQ)UDQNO\,GRQRWWKLQNDERXWLWWKDWPXFK$VORQJDVWKHUHDUHIROORZ
XSVDQGLIDWDQ\WLPHLWGRHVQRWZRUNWKHGRFWRUVZLOOVHHWKDWDQGFKDQJHWKHWUHDWPHQWµ
n ´,ZRXOGOLNHWRWDNHDOOWKHWDEOHWVLQWKHHYHQLQJDQGVWRSWKHPRUQLQJRQH,QWKHHYHQLQJ,DOZD\VWDNHP\WUHDWPHQWEXW,YHU\RIWHQIRUJHW
WRWDNHP\WDEOHWLQWKHPRUQLQJ6RWKH\ZLOOFKDQJHWKHGRVDJHVRWKDW,WDNHWKHWUHDWPHQWRQO\RQFHDGD\µ
o ´,ZDVRQDERDWWULSLQSODFHQDPHDQGLWZDVGLIÀFXOWWRWKLQNDERXWWKDWWDNLQJPHGLFDWLRQZKHQ\RXZHUHRQWKHERDWµ
´1RWIRUJRWEXW,ZDVLQYLWHGWRDEDUEHTXHDQGWKHUHZDVDELWRIDOFRKROVR,GLGQRWWDNHP\GRVHDQG,WKLQNLWLQÁXHQFHGWKHUHVXOWVDELWµ
´<HVLWLVPRUHFRPSOLFDWHGGXULQJWKHWULSEHFDXVH,DPQRWKRPH,GRQRWKDYHWRKLGHEXW,MXVWKDYHWREHPRUHGLVFUHHWHVSHFLDOO\ZKHQ
WKHSHUVRQGRHVQRWNQRZDERXWP\KHDOWKFRQGLWLRQµ
p 6RQRWWDNLQJWKHPHGLFDWLRQUHJXODUO\LVQRWOLQNHGWRDODFNRIFRQÀGHQFHLQ\RXUPHGLFDWLRQ´1R,WKLQNLW·VPRUHFRPSOH[WKDQWKDW,W·VD
ZD\WRGHQ\ZKDWH[LVWV,W·VXQFRQVFLRXV$WWKHPRPHQW,IRUFHP\VHOIWRWDNHLWHYHU\GD\EXWVRPHWLPHV,VOLSµ
q ´,WKRXJKWDERXWLWORRNHGDWWKHSURVDQGFRQVEXWWKHVLGHHIIHFWVWKDW,HQFRXQWHUHG²,DPQRWVD\LQJLW·VWKHFDVHIRUHYHU\RQH²ZHUH
LQVLJQLÀFDQWFRPSDUHGWRWKHEHQHÀWVRIWDNLQJWKHWUHDWPHQWUHJXODUO\µ
Abbreviations:$59DQWLUHWURYLUDOGUXJV+,9KXPDQLPPXQRGHÀFLHQF\YLUXV
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Table 5 Factors affecting ARVs adherence
ARV adherence facilitators
Treatment effectiveness
,QIRUPDWLRQDQGIHHGEDFNDERXWYLUDOORDGDQGFHOOFRXQW
Fear of sexual transmission to partners
3RVVLEOHGHYHORSPHQWRIWUHDWPHQWUHVLVWDQFHZRUU\DERXWWUHDWPHQW
IDLOXUH
6LPSOLÀFDWLRQRI$59UHJLPHQV
Trusting relationship between patients and clinicians
ARVs adherence barriers
0RGLÀFDWLRQVRIWKHGDLO\URXWLQHHJKROLGD\VOXQFKZLWKIULHQGV
3DWLHQW·VXQFRQVFLRXVGHVLUHWRDYRLGWKLQNLQJDERXWWKHGLVHDVH
Food restrictions
Factors with no impact on ARVs adherence
/RQJWHUPKHDOWKSUREOHPVQRDOWHUQDWLYH\HW
6KRUWWHUPVLGHHIIHFWV
'UXJLQWHUDFWLRQVWUXVWLQWKHFOLQLFLDQWRFKRRVHWKHEHVWSRVVLEOH
RSWLRQ
Abbreviation:$59DQWLUHWURYLUDOGUXJV
They talked about impact on their self-esteem, confidence 
and mood overall. Participants did not always perceive that 
their weight gain or excess cellulite was due to medication. 
Some participants reported that medication had a positive 
impact on their lifestyle and body image by taking exercise 
and eating healthily (quotes g and h).
Factors affecting adherence to ARVs
Although many factors were associated with adherence to 
ARVs, most of the patients said they took their treatment in 
accordance with the prescription.
Having information and feedback about their viral 
load and cell count at each medical visit helps patients to 
understand the importance of taking their treatment on a 
regular basis and had a positive influence on their adherence 
(Table 4, i). Patients who reported having confidence in the 
efficacy of treatments also explained the positive impact 
that understanding the medication can have on adherence 
(Table 4, j). A relationship of trust between the patient and 
the doctor is also one of the factors that positively influence 
adherence, particularly by means of patient information, and 
the quality of discussions about side effects and long-term 
effects of treatments.
The fear of sexual transmission to their partners also 
improved adherence to ARVs (Table 4, k). Some patients 
were worried about the possibility of treatment failure or 
the development of treatment resistance and, as a result, 
were aware of the importance of taking their medication 
regularly (Table 4, l). Other patients felt less concerned about 
resistance because they take their medication as prescribed 
and continue to have good test results (Table 4, m). A few 
participants mentioned other factors which affected their 
adherence, including the complexity of the dosing regimen 
for ARVs (Table 4, n).
Conversely, other factors were identified as having a 
negative impact on adherence. These included the social 
life of PLWH (Table 4, o) and the patient’s unconscious 
desire to avoid thinking about the disease (Table 4, p). 
Finally, experiencing side effects (such as diarrhea, fatigue 
or nausea and lipodystrophy) did not impair treatment adher-
ence (Table 4, q). Factors affecting adherence are synthetized 
in Table 5.
Discussion
This study provides new insights into the importance 
that PLWH place on certain attributes of ARV therapy. 
The relationship between treatment satisfaction and certain 
characteristics of ARVs has been evaluated previously in a 
small number of qualitative studies. Quantitative approaches 
such as DCE, in which patients are asked to choose between 
treatments attributes and make trade-offs, provide additional 
information since they allow the relative importance of these 
attributes to be compared. Nonetheless, direct qualitative 
assessment allows more exhaustive coverage of the aspects 
of ARV treatment that are important to patients. For this 
reason, it is of interest to combine quantitative (DCE) and 
qualitative approaches in the same study.
In the quantitative study, the DCE attributes of the treat-
ment can be categorized into those relating to quality of life 
(diarrhea, long-term health problems), those relating to taking 
the treatment (DDI and food restrictions) and those relating to 
the efficacy of the treatment (viral load, CD4 cell count and 
treatment failure). The ORs showed that patient placed most 
importance on attributes which can have an impact on quality 
of life and taking treatment, rather than those affecting effi-
cacy. One possible explanation for this could be that the study 
sample included patients experienced with ARTs whose 
infection was well controlled. For this reason, they may be 
aware that their treatment is effective and may take this for 
granted when making treatment choices. Furthermore, the 
DCE results also underline that treatments with a risk of DDI 
are a concern when choosing ARVs. Although this appeared 
to be a constraint only for the doctor, it is also a concern 
for the patient, and may increase with the patients’ age and 
associated comorbidities.39,40 This study is the first one carried 
out using discrete choice methods relating to satisfaction of 
PLWH treated with ARVs in France. A recently published 
study exploring 131 physicians’ views of patient treatment 
preferences in Germany found that avoiding treatments that 
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caused visible signs of disease, avoiding diarrhea and nausea, 
and empowering patients to self-administer treatment, were 
attributes that had the biggest impact on patient preference 
for treatment.41 The attributes evaluated in this study were 
different from those in ours but, in both studies, attributes 
related to quality of life emerged as key factors.
Analysis of the qualitative data on treatment attributes 
provided support for the findings of the DCE, highlighting 
the importance patients place on treatment efficacy and 
demonstrating the importance of other characteristics, such 
as concerns about potential long-term impact of treatments. In 
a trade-off, patients will choose a treatment with as few side 
effects and long-term health problems as possible, and as low 
a risk of treatment failure and DDI as possible. Moreover, 
when interviewed separately on each attribute, and based on 
their current treatment, they conceded that certain negative 
attributes, such as side effects, were acceptable, because 
they were otherwise satisfied with their current treatment in 
terms of efficacy and convenience. Patients were aware of 
the risk of treatment failure and DDI, but they trusted their 
doctor’s prescription.
Many factors influencing treatment satisfaction were 
revealed through the qualitative analysis, including pill size, 
effectiveness of medication, worry about sexual transmission 
and impact on social life. Opportunities for improving treat-
ments to increase patient satisfaction and adherence were also 
highlighted, notably less visible packaging to limit stigmati-
zation, smaller and more discreet tablets, greater flexibility 
in taking doses and fewer food restrictions.
The qualitative analysis indicated that certain treatment 
attributes may influence adherence. For example, for many 
patients, having a good understanding of the expected ben-
efits and risks of their treatment had a positive impact on their 
adherence. This is consistent with previous studies, which 
have found that adherence was influenced by how effective 
patients perceived their medication to be. For example, a 
large European study showed effectiveness to be one of the 
most important determinants of adherence.11,13 Many patients 
discussed the importance of receiving feedback from their 
clinician about viral load and CD4 cell count and some 
patients said the trust they had in their clinician gave them 
confidence in the effectiveness of their treatment. To encour-
age adherence, it is, therefore, important to develop tools 
to monitor changes in the biological efficacy of treatment. 
This need is reflected in current approaches to therapeutic 
education in France. This finding is also consistent with those 
of previous studies demonstrating the important role that 
clinicians play in treatment satisfaction and adherence, and 
underlines the importance of the quality of clinician–patient 
dialogue in optimizing patient satisfaction and adherence 
to treatment.24,26
Regarding the external validity of the overall study, 
patients from both parts of the study had similar charac-
teristics and sampling provided a representative group of 
patients regularly seen in medical consultation.42 The major-
ity of patients in this study had been taking ARV treatments 
for a number of years and had switched treatments at least 
twice, so were highly experienced in treatment for HIV. 
Nonetheless, given the relatively small size of the sample, 
it was difficult to stratify the patient sample to cover the 
anticipated spread of sociodemographic characteristics of 
PLWH in order to obtain a representative sample. For this 
reason, the advisory board proposed that sampling patients 
consecutively from a clinic list would be more appropriate, 
in order to avoid physicians targeting patients from particular 
demographic groups that would be more engaged with the 
process.
Certain patients were included in both studies to facili-
tate patient recruitment. However, the risk that patients’ 
responses may be biased due to participation in both studies 
was considered to be limited.
Certain limitations associated with the DCE methodol-
ogy should be considered. This powerful multidimensional 
tool is used to analyze simultaneously the influence of 
multiple attributes, the ORs providing information about 
the relative importance of each attribute. However, the 
performed analysis does not allow comparison of the 
ORs between the different attributes. It is also difficult to 
compare the importance of different attributes, expressed 
in different units. For example, the viral load is expressed 
as copies/mL, whereas other attributes are presented as 
probabilities or categorical variables. Finally, although the 
chosen attributes and their levels had been selected from a 
literature review and from discussion with clinicians and 
expert patients, it is possible that other characteristics of 
treatments influencing patient preferences were not evalu-
ated. One of the main limitations of the qualitative part of 
the study is that the trends and themes developed are only 
representative of those patients in the study sample and may 
not be generalized to represent the views of PLWH across 
the whole country.
Conclusion
This study provides a new light on preferences of PLWHs 
regarding different attributes associated with ARV 
therapies and on the main factors associated with PLWH 
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satisfaction. One of the key results is the importance placed 
by PLWHs on characteristics of ARVs related to quality 
of life, in particular for ARV therapy with no increased 
risk of long-term health problems and side-effects. This 
should be taken into consideration when prescribing ARV 
therapies, in order to optimize adherence and satisfaction 
of PLWHs.
These data will be compared to those from the four 
other participating European countries in order to identify 
similarities and differences in the factors influencing patient 
satisfaction and preferences between countries.
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